SARS-CoV-2 Detection from the Built Environment and Wastewater and Its Use for Hospital Surveillance

Aaron Hinz[1,6], Lydia Xing[2], Evgueni Doukhanine[3], Laura A. Hug[4], Rees Kassen[1], Banu Ormeci[5], Richard J. Kibbee[5], Alex Wong[6], Derek MacFadden*[2,7], Caroline Nott*[2, 7]

*Co-PIs

1. Department of Biology, University of Ottawa, Ottawa, ON Canada
2. Division of Infectious Diseases, Department of Medicine, University of Ottawa, ON Canada
3. DNA Genotek, Inc., Ottawa, ON, Canada
4. Department of Biology, University of Waterloo, ON Waterloo
5. Department of Civil and Environmental Engineering, Carleton University, Ottawa, ON Canada
6. Department of Biology, Carleton University, Ottawa, ON Canada
7. The Ottawa Hospital Research Institute, Ottawa, ON Canada

Corresponding Author: Aaron Hinz, Department of Biology, University of Ottawa, 30 Marie-Curie, Ottawa, ON K1N6N5. Email: ahinz@uottawa.ca

ABSTRACT

Background. SARS-CoV-2 causes significant morbidity and mortality in health care settings. Our understanding of the distribution of this virus in the built healthcare environment and wastewater, and relationship to disease burden, is limited.

Methods. We performed a prospective multi-center study of environmental sampling of SARS-CoV-2 from hospital surfaces and wastewater and evaluated their relationships with regional and hospital COVID-19 burden. We developed and validated a qPCR-based approach to surface sampling, and swab samples were collected weekly from different locations and surfaces across two tertiary care hospital campuses for a 10-week period during the pandemic, along with wastewater samples.

Results. Over a 10-week period, 963 swab samples were collected and analyzed. We found 61 (6%) swabs positive for SARS-CoV-2, with the majority of these (n=51) originating from floor samples. Wards that actively managed patients with COVID-19 had the highest frequency of positive samples ($p<0.01$). Detection frequency in built environment swabs was significantly associated with active cases in the hospital throughout the study ($p<0.025$). Wastewater viral signal changes appeared to predate change in case burden.

Conclusions. Environment sampling for SARS-CoV-2, in particular from floors, may offer a unique and resolved approach to surveillance of COVID-19.

Key Words: SARS-CoV-2, COVID-19, environmental screening, burden, wastewater

BACKGROUND

COVID-19 has caused substantial morbidity and mortality worldwide since it was first identified at the end of 2019. Despite the development of effective vaccines and the discovery of multiple therapeutic agents[1,2], the SARS-CoV-2 virus and agent of COVID-19 continues to transmit across all corners of the globe. As of Spring 2021, it is estimated that over 100 million people have been infected with SARS-CoV-2 from the start of the pandemic, with over 2.5 million deaths attributable to COVID-19[3].

Hospitals were recognized early on as a potentially high-risk environment for acquiring COVID-19 infection for patients and healthcare workers, with healthcare facility outbreaks and nosocomial acquisition of COVID-19 common and well described[4]. While the respiratory droplet route is considered to be a primary means for transmission of SARS-CoV-2 in hospitals, it is still not well established if there is appreciable transmission through contact with the built environment[4,5], and to what extent this could contribute to spread.

Laboratory experiments indicate that the virus can remain viable on stainless steel and plastics for approximately 6 hours and SARS-CoV-2 RNA can be detected from wastewater[6]. Preliminary studies have shown a range from no to extensive contamination of hospital ward surfaces, including computer mice, trashcans, and door handles[7]. In addition to identifying the potential routes for fomite-based transmission, surveying the distribution of SARS-CoV-2 throughout the hospital environment over time can provide insight into hospital burden and potentially outbreak identification and monitoring. New approaches for early outbreak detection will be particularly important to reduce institutional morbidity and mortality[8]. The built environment presence of SARS-CoV-2 could act as a spatially resolved indirect measure of symptomatic and asymptomatic carriage/infection within patients and healthcare workers

75 (HCWs). In a similar fashion, wastewater surveillance may offer a less spatially resolved but
76 potentially anticipatory mechanism for hospital COVID-19 surveillance and monitoring[9,10].
77
78 In this study, we conducted a longitudinal assessment of the prevalence of SARS-CoV-2 on
79 commonly contacted hospital surfaces as well as from hospital wastewater and compared these
80 markers with active COVID-19 case prevalence at two large tertiary care hospitals and in the
81 surrounding community.
82
83 **METHODS**
84

85 **SARS-CoV-2 control samples**

86 Control samples of heat-inactivated SARS-CoV-2 (ATCC VR-1986HK; lot 70035039) and
87 SARS-CoV-2 RNA (ATCC VR-1986D; lot 70035624) were obtained from Cedarlane
88 Laboratories. The copy numbers of the control samples were reported as 4.73 x 10^3 genome
89 copies/µL for the RNA and 3.75 x 10^5 genome copies/µL for the heat-inactivated virus.
90

91 **Swabbing method and validation**

92 Surfaces were sampled with P-208 Environmental Surface Collection Prototype kit from DNA
93 Genotek, consisting of a flocked swab and a semi-lytic nucleic acid stabilization solution for
94 post-collection swab immersion. The swabbing method was validated in laboratory experiments
95 using surface materials spiked with heat-inactivated SARS-CoV-2. We applied 10^5 copies of the
96 virus to sheets of acrylic, stainless steel, and vinyl upholstery by pipetting 150 µl of virus
97 suspension in 30-40 small spots within a 2.25 in by 2.25 in square. After a 2.5 hour drying

98 period, swabs were pre-wetted with stabilization solution, surfaces were swabbed for 30
99 seconds, and swabs were stored in stabilization solution in collection vials. As controls, sterile
100 swabs were placed in collection vials containing virus spiked directly into the stabilization
101 solution. Following one day of storage at room temperature, RNA was extracted and analyzed
102 by qPCR. The amount of virus in each sample was estimated using the virus standard curve
103 that relates Cq values to input genome copies. The percent viral recovery was determined by
104 dividing the amount of virus estimated for the surface swabbed samples by the amount of virus
105 estimated in the control samples. Significant differences in recovery efficiencies across surfaces
106 were determined by ANOVA with post hoc comparisons using Tukey's honestly significant
107 difference (HSD) test.

108

109 **RNA extractions and RT-qPCR**

110 Presence of SARS-CoV-2 RNA was determined by quantitative reverse-transcriptase PCR (RT-
111 qPCR) of RNA extracted from swab sample stabilization solution. RNA was extracted from
112 samples using the MagMAX Viral/Pathogen II (MVP II) Nucleic Acid Isolation Kit (Thermo-Fisher
113 Scientific) according to the manufacturer’s protocol, with reagent volumes modified
114 proportionally for 300 µl sample input volumes. Extractions were performed in batches of up to
115 96 in deep-well plates. Each batch included positive (heat-killed SARS-CoV-2) and negative
116 (stabilization solution only) control samples to monitor extraction efficacy and potential cross-
117 contamination. None of the control samples yielded false positive or false negative results.

118

119 Quantitative PCR was performed with primers and a TaqMan probe targeting the N gene of
120 SARS-CoV-2 (Table 1). The probe contained a 6-carboxyfluorescein (FAM) fluorescent dye at

121 the 5' end and the minor groove binder non-fluorescent quencher (MGB-NFQ) at the 3' end.
122 Each qPCR reaction consisted of 5 µl of extracted RNA, 300 nM of each primer, 200 nM of
123 probe, and 5 µl of 4X TaqPath 1-Step Multiplex Master Mix (No ROX) (Applied Biosystems) in a
124 final volume of 20 µl. Thermal cycling, fluorescence quantification, and quantitative cycle (Cq)
125 determination were performed on a Bio-Rad CFX Connect with the following cycling conditions:
126 25 °C for 2 min, 50 °C for 15 min, 95 °C for 2 min, and 45 cycles of denaturation (95 °C for 3 s)
127 and elongation (55 °C for 30 s).

128

129 **Estimates for Limits of Detection and Quantification**

130 Analytical sensitivity and precision of the qPCR assays were determined by estimating the limits
131 of detection and quantification of the SARS-CoV-2 RNA and virus standards. Serial 10-fold
132 dilutions of the SARS-CoV-2 RNA standard were analyzed by qPCR with 14-20 replicates per
133 dilution. For the virus standard, RNA was extracted from serial dilutions of heat-inactivated virus
134 (7 replicate extractions at each dilution) prior to qPCR analysis.

135

136 The qPCR results were analyzed as described by Klymus et al.[12] using the Limit of Detection
137 (LOD) Calculator (R script available at: https://github.com/cmerkes/qPCR_LOD_Calc). The
138 standard curves were modeled as linear regressions based on the middle two quartiles of Cq
139 values for each standard concentration exhibiting >50% detection. The limit of detection was
140 defined as the lowest input amount that was detected in >95% of replicates, and the limit of
141 quantification was defined as the lowest input amount yielding reproducible Cq values with a
142 coefficient of variation less than 0.35. For the RNA standards, the LOD with 95% confidence
143 intervals and limit of quantitation (LOQ) were determined by a curve-fitting approach as

144 described[12]. The virus LOD was estimated using a discrete threshold (*i.e.*, the lowest tested
145 input amount with >95% detection).

146

147 **Built Environment Sample Collection**

148 We prospectively collected built environment swabs from two large tertiary-care, academic
149 hospital campuses (Campus A and Campus B) from Ottawa, Ontario, Canada over a 10-week
150 period between September 28 and December 6, 2020. We obtained between 40-50 samples
151 from each campus weekly, generally maintaining location and surface type longitudinally,
152 though we did not attempt to sample the exact same item longitudinally in order to improve our
153 study generalizability. For example, a computer keyboard sampled in week 1 on Unit A, may be
154 different from a computer keyboard sampled on Unit A in week 2. At both campuses, we
155 collected samples from 1 COVID-dedicated unit, 1 ICU (COVID-designated area), 1 Emergency
156 Department (ED) area, non-COVID medical and surgical units (n=3 at Campus A, n=4 at
157 Campus B), 1 ambulatory unit (dialysis), public/non-patient-care spaces within the hospital (e.g.
158 main elevators), and exterior hospital grounds (e.g. parking garage). A designated HCW space
159 was also sampled at Campus A. Built environment samples were collected by wetting a P-208
160 kit flocked swab with the stabilization media, and sweeping the swab tip across an
161 approximately 2” x 2” area (dependent upon the item/surface size) for approximately 30
162 seconds. The swab was then transported in the P-208 stabilization media, and stored at
163 ambient temperature to be processed/analyzed within 1 month of collection. Three study
164 authors (LX, DM, CN) collected the samples during the study period, and swab technique was
165 harmonized between them at onset of sample collection. A run-in week was performed prior to
166 week 1, in order to test sample collection, logistics, and sample processing, but is not included

167 in this analysis as a number of specimen sites were initially not included for this week, making
168 inter-week comparisons challenging.
169
170 Specific (non-critical care) wards in the hospital were designated for the ongoing inpatient care
171 of COVID patients, and these were designated as 'COVID Wards'. However, we classified both
172 the COVID Wards as well as the ICU and ED as 'COVID Risk Units', because they were
173 anticipated to be managing a large number of SARS-CoV-2 infected patients.
174
175 **Hospital Practices**
176 The visitor policy at the start of the study period limited visitation to 1 visitor/patient/day;
177 however, at the start of study week 4, visitors were further restricted to essential caregivers
178 only. Environmental cleaning was in keeping with provincial best practice and occurred daily in
179 both public and clinical areas, with all contact points disinfected with Vert-2-Go© everyday
180 disinfectant (quaternary-ammonium based product) and floors mopped with Vert-2-Go© Oxy
181 floor cleaner. The only deviation from this was once weekly cleaning of the Campus A parking
182 garage until sometime between study weeks 5-7, then once daily thereafter. Infection
183 Prevention and Control (IPAC) policies were also consistent with provincial best practice[6,13] .
184 Throughout the study period, all staff, visitors, and patients were screened for COVID-19
185 symptoms and risk factors (e.g. exposures, international travel) on entry to the hospital, in
186 accordance with Ontario Ministry of Health guidance[14]. Universal masking for all staff and
187 visitors was introduced prior to the study period. Universal eye protection (visor or goggles) for
188 staff working in clinical areas was introduced at the start of study week 1.
189
190
191 **Wastewater Sample Collection**

192 Raw sewage grab samples from Campus A were taken with a 5L bucket on a rope between
193 11:10am and 12:30pm each sampling day, which occurred once every 1 to 2 weeks during (and
194 immediately prior to) the study period. The samples were swirled in the bucket and quickly
195 poured into pre-labelled sterile 1L Nalgene bottles which were immediately placed into a cooler
196 with ice packs for transport back to the lab and processed within 1 hr. Temperature of the
197 samples, measured at the time of sampling with an infrared thermometer, for Oct-Dec were
198 between 12 and 22 ºC. A 200ml aliquot was concentrated to 0.25-1.25ml using the Centricon®
199 Plus-70 (MilliporeSigma) centrifugal ultrafilter with a cut-off of 10 kDa[15]. The resulting
200 concentrate was extracted using the RNeasy PowerMicrobiome Kit (QIAGEN) according to the
201 manufacturer's instructions with an elution of 100µl.
202
203 Primers and probes, and Real-Time Reverse Transcriptase (RT RT-PCR) methods developed
204 by the US CDC were used with the Bio-Rad CFX96 Touch Real-Time PCR Detection System.
205 The RT RT-PCR thermal cycling protocol used to amplify the target region within the SARS-
206 CoV-2 nucleocapsid gene, N2, was carried out at 50 °C for 30 minutes, followed by 95 °C for 15
207 minutes and 50 cycles of 95 °C for 15 and 60 °C for 30 seconds. Reaction mixture for RT RT-
208 PCR, 5 µl RNA template, 4 µl of QIAGEN OneStep RT-PCR 5x Buffer, 2 µl dNTP mix (10 mM
209 each), 2 µl Enzyme Mix, Primers and Probes were used at 500nM/reaction, and 2 µl of 4 mg/ml
210 BSA. Each reaction volume was adjusted to a final volume of 20 µl with RNase-free water. Each
211 sample was run in duplicate. An MS-2 bacteriophage matrix spike whole process control was
212 used to assess the efficiency of the concentration process and RNA extraction as well as
213 confirm RT RT-PCR protocols. RT RT-PCR inhibition control using MS2 bacteriophage spiked
214 into raw sewage RNA extracts and molecular grade water was used to assess the performance
215 of the RNA-extraction, RT-PCR and to detect the presence of inhibitors. Quantification of the N2
216 gene target in the raw sewage sample concentrates was done using standard curves created
217 with a 2019-nCoV_N_Positive Control plasmid (IDT, Inc.) Non-template controls (NTC) were run

218 for each mastermix preparation with molecular grade water as the template. For each week
219 under observation, we averaged the detectable copies/ml from both N1 and N2 gene targets.
220
221
222 **Hospital and Citywide COVID-19 Cases and Outbreaks**
223 Daily active patient COVID-19 case counts and locations, including admitted and non-admitted
224 Emergency Department cases, were obtained from Infection Prevention and Control (IPAC).
225 Cases were those confirmed by RT-PCR. We generated a measure of weekly 'active' COVID-
226 19 cases by taking the mean of these daily active cases for each week (typically data only
227 available for weekdays). Healthcare worker (HCW) cases were not included in the analysis, as
228 HCWs were more likely than patients to spend time on multiple units and move throughout the
229 hospital. Also, once a HCW became symptomatic or had a positive COVID-19 test result, they
230 would no longer remain within the hospital. Hospital outbreak data were obtained in real time
231 from IPAC and verified post-study on the publicly available Ottawa Public Health (OPH) COVID-
232 19 dashboard[16]. An outbreak was defined as per the Ontario Ministry of Health[17] as, "Two or
233 more laboratory-confirmed COVID-19 cases (patients and/or staff) within a specified area
234 (unit/floor/service) within a 14-day period where both cases could have reasonably acquired
235 their infection in the hospital". New and total active COVID-19 cases in Ottawa were obtained
236 daily from the OPH COVID-19 dashboard, and a weekly 'active' caseload was calculated as the
237 mean of the daily active cases across a given week.
238
239 **Data Analysis**
240 To evaluate the characteristics associated with positive swab results, we performed a linear
241 regression model using specimen characteristics as predictors of built environment sample
242 positivity (total or floor specific specimens). Specimen characteristics were coded as categorical
243 variables, including unit COVID Risk type, object/site, material, study week. The outcome

244 (sample positivity) was coded as a binary variable (1=detected, 0=not-detected). A linear model
245 was used to predict the outcome variable as it provided improved interpretability of coefficients
246 and also model convergence stability[18].
247
248 We also evaluated the strength of associations between (i) proportion of hospital built
249 environment swabs positive for SARS-CoV-2 and (ii) proportion of hospital floor swabs positive
250 for SARS-CoV-2, and hospitalized active COVID-19 cases. We used a negative-binomial
251 regression model with active cases as the outcome. We did not quantitatively evaluate the
252 association between wastewater and active cases because of the limited number of wastewater
253 data points.
254
255 For the majority of the analyses we analyzed the two campuses in combination, as they reflect a
256 single health care center with transfer occurring within and between units in both campuses. We
257 also chose not to evaluate case burden by specific unit because, in general, as soon as a case
258 was identified on a given non-COVID risk unit, the patient would be transferred to a specific
259 COVID Risk unit either for cohorting or due to severity of illness (e.g. ICU).
260
261 All statistical analyses were performed using R (Version 4.0.3). Research ethics board approval
262 was obtained through the Ottawa Health Science Network Research Ethics Board (OHSN-REB)
263 for this study.
264

265 **RESULTS**

266

267

268 **Limit of Detection and Swab Validation**

269 We detected and quantified SARS-CoV-2 RNA by qPCR analysis using the N1 primer and
270 probe set targeting the nucleocapsid gene[11]. A standard curve relating the quantification cycle
271 (C_q) values to viral genome copy number was produced by analyzing a 10-fold dilution series of
272 a SARS-CoV-2 RNA standard (Fig. 1A). We used a model-fitting approach to determine the
273 LOD, defined as a detection rate greater than 95%, and LOQ defined as a C_q coefficient of
274 variation less than 0.35[12]. Reactions containing at least 3 genome copies were reliably detected
275 under our qPCR conditions, whereas precise quantification required at least 150 copies (C_q <
276 30) (Fig. 1A).

277

278 Analysis of the built environment swab samples involved a nucleic acid extraction step prior to
279 qPCR analysis. We evaluated the extraction method by qPCR analysis of RNA extracted from
280 samples of a heat-inactivated SARS-CoV-2 virus standard (Fig. 1B). The LOD for the virus
281 standard (28 copies per reaction) was ~10-fold higher than that of the RNA standard, which can
282 be due to RNA loss during the extraction procedure, presence of PCR inhibitors in the eluant, or
283 inaccuracies in the reported titers of the standards. Nevertheless, the procedure was sensitive
284 and reproducible, and the results yielded a linear standard curve for converting C_q values to viral
285 copies while accounting for inaccuracies introduced by sample processing.

286

287 The built environment sampling approach relied on recovery of virus particles and nucleic acid
288 from surfaces. In preliminary tests, we determined how efficiently our swabbing technique
289 recovered virus from surface types representative of the built environment: acrylic, stainless
290 steel, and vinyl. The surfaces were spiked with equal amounts of heat-inactivated virus, allowed
291 to dry, and swabbed by the procedure used for built environment sampling. Following incubation
292 of the swabs in stabilization solution and qPCR analysis of extracted RNA, we estimated the
293 amount of recovered virus using the virus standard curve and calculated the percent of virus
294 recovered from each surface (Fig. 2). The mean recovery efficiencies ranged from 28 to 42%
295 across the three surfaces, values similar to those reported in a previous study of SARS-CoV-2
296 surface swabbing[19].

297

298 **Built Environment Screening**

299 Over a 10-week period from September 28th to December 6th 2020 we systematically
300 performed 963 built environment swabs across 2 tertiary care hospital sites. SARS-CoV-2 was
301 detected from 6% of swabs (61/963), and was most commonly found from floor samples, with a
302 detection prevalence of 27% (51/188). SARS-CoV-2 was less frequently identified from elevator
303 buttons, benches, items (*e.g.*, hand sanitizer pumps), and computer keyboards.

304

305 COVID Risk units, namely COVID treatment wards, intensive care units, and emergency rooms,
306 were the most common locations to find SARS-CoV-2 in the hospital environment, with
307 detection prevalence of 18%, 8%, and 7% respectively (Table 2, Fig. 3). Non-COVID and
308 public/HCW spaces tended to have a low frequency of SARS-CoV-2 detection from the
309 environment. During the course of this study, there were 2 outbreaks involving study units, at
310 Campus B in the ED (1 patient and 2 HCW) and at Campus A on Ward 3 (5 patients and 1

311 HCW). A third outbreak occurred on a non-COVID inpatient unit at Campus A but this unit was
312 not sampled in the study.
313
314 Across the 10-week study period, SARS-CoV-2 detection prevalence paralleled total active
315 cases across the two hospital campuses. Viral prevalence gradually declined over time, but with
316 spikes in hospitalized cases being clearly reflected in built environment burden (Figure 4A), as
317 well as an increase reflecting the start of hospitalizations in the second wave of the pandemic
318 within the city. Built environment burden also paralleled citywide cases, but with less
319 concordance (Figure 4B). Campus B tended to have SARS-CoV-2 positivity largely restricted to
320 COVID Risk units, but Campus A seemed to have more activity in non-COVID risk units/public
321 spaces. A multi-variable logistic regression model identified that increasing study week was
322 associated significantly with reduced detection of SARS-CoV-2 ($p<0.05$), and that COVID Risk
323 units and Campus A were significantly associated with increased SARS-CoV-2 detection (Table
324 3, Table 4).
325
326 Hospital floors were the most common surface from which SARS-CoV-2 was detected. We
327 looked specifically at prevalence on floors and its relationship with cases within the hospital and
328 citywide (Figure 5). Restricting analysis to only floors showed they parallel the findings seen
329 with all samples (Figures 4), with stronger correlation with active hospital cases.
330
331 Hospital wastewater SARS-CoV-2 viral copies per ml (Figure 6) followed a similar trajectory as
332 built environment sampling but decline in wastewater levels appeared to predate both the built
333 environment sampling as well as Campus A and citywide case burden.
334
335 We also evaluated the strength of association between (i) all built environment swab positivity
336 and (ii) floor swab positivity with hospital case burden (Table 4). We found that floor swabs best

337 described the hospital case burden, having a measure of association with the greatest
338 precision, and the model with the lowest AIC (Table 4).
339
340
341 **DISCUSSION**
342
343
344 In this prospective longitudinal study at two large tertiary care hospital campuses, we
345 demonstrate that SARS-CoV-2 RNA can be readily identified from a variety of hospital surfaces
346 as well as hospital wastewater. Moreover, both the relative frequency of isolation on surfaces
347 and the viral titre in wastewater parallel the burden of infection within the hospital. Wards that
348 specifically managed COVID-19 patients had consistently higher levels of detection compared
349 to other areas, and frequency of detection paralleled case counts over time. For the single ward-
350 based outbreak that occurred during the study period, there was detectable viral RNA at the
351 involved location from the onset and until resolution.
352
353 Prior studies have demonstrated the amplification of SARS-CoV-2 RNA from the hospital
354 environment[7] including high touch surfaces outlined in this paper (*e.g.*, elevator buttons,
355 computer keyboards, alcohol hand pumps). Floors have been identified as a common location
356 for identifying SARS-CoV-2 in hospitals, and our results reinforce this finding[7]. Moreover, we
357 found that performing surveillance from floors provided the best marker for predicting hospital
358 burden of infection.
359
360 To date, fomites have not been identified as a major contributor to transmission of SARS-CoV-2
361 in the hospital or other settings[5]. While our PCR-based approach for SARS-CoV-2 RNA
362 detection cannot identify whether viral particles present in our samples were viable or not, our

363 results do indicate that identifying any RNA from high touch surfaces is relatively rare, further
364 supporting these as unlikely pathways for transmission in hospitals. Floors, however, were a
365 common location for SARS-CoV-2 RNA in our study. It is likely they represent a sink for viral
366 particles which originate from the respiratory droplets/aerosol from patients, health workers, or
367 visitors, and it is unlikely that floors represent a reservoir for transmission[7].
368
369 Interestingly, the non-COVID ward, Ward 3 on Campus A, that experienced the outbreak had
370 frequent detection of SARS-CoV-2 during the outbreak period, with general absence before and
371 after. This suggests that built environment sampling may offer a way to potentially identify occult
372 outbreaks or transmission occurring within patients/visitors/healthcare workers or for monitoring
373 outbreak status. The outbreak that occurred in the ED at Campus B did have a brief but non-
374 sustained signal, and we believe this is related to the transient nature of patients (and flux of
375 staff) within the ED. Patients are flowing from the ED itself to either discharge or transfer to
376 other sites within the hospital, thus it is unlikely to sustain a patient-based outbreak within that
377 area. The reason for higher detection of SARS-CoV-2 at Campus A is likely driven by more
378 frequent detection at non-COVID risk unit sites. The reason for this is unclear and may relate to
379 both patient and visitor populations.
380
381 Where built environment sampling can provide a resolved view of COVID-19 burden in the
382 hospital, hospital wastewater can provide institution-wide surveillance with the possibility for
383 anticipatory (predictive) signals. Qualitatively, wastewater appeared to anticipate burden by 1-2
384 weeks, and is on the order of magnitude reported in the literature[20], though given the limited
385 number of time points, we were not able to confirm this statistically. A growing number of
386 studies have shown the potential benefit of wastewater monitoring in both regional as well as
387 facility-based surveillance[20,21], and our study links this surveillance as complementary to built
388 environment screening. Combined approaches may ultimately be applicable to other respiratory

389 viruses that cause significant institutional outbreaks, including influenza, though further
390 validation is needed.
391
392 Our study has some limitations which have not already been noted. Firstly, our study was
393 performed during a period when there was relatively low activity, with regional case counts
394 ranging from approximately 2 to 7 cases per 100,000 population per week, and it is possible that
395 in higher burden settings there could be saturation of ward-based built environment detection
396 which could limit the correlation with burden or outbreaks. Secondly, outbreaks were relatively
397 rare in our hospital, owing in part to the low regional burden, and this limits our ability to
398 evaluate the ability of built environment screening to consistently detect outbreaks. Lastly, our
399 approaches only detect viral RNA and not viable virus. However, our findings benefit from the
400 generalizability of our approaches which use standard PCR techniques and could be easily and
401 quickly performed in most settings worldwide.
402
403 In conclusion, we have demonstrated that the detection of SARS-CoV-2 from wastewater and
404 built environment samples, in particular from floors, parallels hospital burden. Built environment
405 sampling may offer a spatially-resolved method for surveillance of hospital COVID-19 cases
406 which can be paired with wastewater monitoring for a comprehensive picture of facility-wide
407 burden of infection. Further prospective studies are needed to evaluate this approach.
408
409 **Acknowledgements.** We would like to thank Dr. Kathryn Suh and Dr. Raphael Saginur for their
410 support and advice during this study. We would also like to thank the City of Ottawa Wastewater
411 Collection Branch, and in particular Benjamin Musyoka and Sandra Gay, for accomodating the
412 collection of wastewater samples.
413

414 **Author's contributions.** All authors contributed to the design of the study. LX, DM, CN
415 collected built environment samples for the study and performed data entry. RJK and AH
416 processed samples for the study. DM and CN contributed to data analyses. All authors
417 contributed to the writing of the manuscript.
418
419 **Financial support.** This work was supported by The Ottawa Hospital Academic Medical
420 Organization (TOHAMO), Alliance Grant # 554478 - 20 from the Natural Sciences and
421 Engineering Research Council (NSERC), Carleton University Rapid Response Research Grant,
422 and the Jarislowsky Foundation.
423
424 **Potential conflicts of interest.** Author ED works for DNA Genotek which provided sampling
425 swabs in-kind for this study in an unrestricted fashion. DNA Genotek had no control over the
426 findings, interpretations, or conclusions published in this paper. All other authors have no
427 relevant conflicts to disclose.

428 **REFERENCES**

429 1. Siemieniuk, R. A. C. *et al.* Drug treatments for covid-19: living systematic review and
430 network meta-analysis. *BMJ* **370**, (2020).
431 2. Baden, L. R. *et al.* Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N. Engl.*
432 *J. Med.* **384**, 403–416 (2021).
433 3. The Visual and Data Journalism Team. Covid map: Coronavirus cases, deaths,
434 vaccinations by country. *BBC News* https://www.bbc.com/news/world-51235105 (2021).
435 4. Islam, M. S. *et al.* Current knowledge of COVID-19 and infection prevention and control
436 strategies in healthcare settings: A global analysis. *Infect. Control Hosp. Epidemiol.* **41**,
437 1196–1206 (2020).
438 5. Mondelli, M. U., Colaneri, M., Seminari, E. M., Baldanti, F. & Bruno, R. Low risk of SARS-
439 CoV-2 transmission by fomites in real-life conditions. *Lancet Infect. Dis.* (2020)
440 doi:10.1016/S1473-3099(20)30678-2.
441 6. van Doremalen, N. *et al.* Aerosol and Surface Stability of SARS-CoV-2 as Compared with
442 SARS-CoV-1. *N. Engl. J. Med.* **382**, 1564–1567 (2020).
443 7. Guo, Z.-D. *et al.* Aerosol and Surface Distribution of Severe Acute Respiratory Syndrome
444 Coronavirus 2 in Hospital Wards, Wuhan, China, 2020. *Emerg. Infect. Dis.* **26**, 1583–1591
445 (2020).
446 8. Smith, D. R. M. *et al.* Optimizing COVID-19 surveillance in long-term care facilities: a
447 modelling study. *BMC Med.* **18**, 1–16 (2020).
448 9. Westhaus, S. *et al.* Detection of SARS-CoV-2 in raw and treated wastewater in Germany -
449 Suitability for COVID-19 surveillance and potential transmission risks. *Sci. Total Environ.*
450 **751**, 141750 (2021).
451 10. Gonçalves, J. *et al.* Detection of SARS-CoV-2 RNA in hospital wastewater from a low
452 COVID-19 disease prevalence area. *Sci. Total Environ.* **755**, (2021).

453 11. CDC. Labs. https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html
454 (2020).
455 12. Klymus, K. E. *et al.* Reporting the limits of detection and quantification for environmental
456 DNA assays. *Environmental DNA* **2**, 271–282 (2020).
457 13. Public Health Ontario. https://www.publichealthontario.ca/-/media/documents/b/2020/bp-
458 novel-respiratory-infections.pdf?la=en.
459 14. Ontario Ministry of Health. http://health.gov.on.ca/en/pro/programs/publichealth/
460 coronavirus/docs/2019_reference_doc_symptoms.pdf.
461 15. Medema, G., Heijnen, L., Elsinga, G., Italiaander, R. & Brouwer, A. Presence of SARS-
462 Coronavirus-2 RNA in sewage and correlation with reported COVID-19 prevalence in the
463 early stage of the epidemic in the Netherlands. *Environ. Sci. Technol. Lett.* **7**, 511–516
464 (2020).
465 16. Daily COVID-19 Dashboard. https://www.ottawapublichealth.ca/en/reports-research-and-
466 statistics/daily-covid19-dashboard.aspx (2021).
467 17. Ontario Ministry of Health. http://www.health.gov.on.ca/en/pro/programs/publichealth/
468 coronavirus/docs/2019_acute_care_guidance.pdf.
469 18. Gomila, R. Logistic or linear? Estimating causal effects of experimental treatments on
470 binary outcomes using regression analysis. *J. Exp. Psychol. Gen.* (2020)
471 doi:10.1037/xge0000920.
472 19. Parker, C. W. *et al.* End-to-End Protocol for the Detection of SARS-CoV-2 from Built
473 Environments. *mSystems* **5**, (2020).
474 20. SARS-CoV-2 RNA in wastewater anticipated COVID-19 occurrence in a low prevalence
475 area. *Water Res.* **181**, 115942 (2020).
476 21. Sharif, S. *et al.* Detection of SARs-CoV-2 in wastewater, using the existing environmental
477 surveillance network: An epidemiological gateway to an early warning for COVID-19 in
478 communities. *medRxiv* 2020.06.03.20121426 (2020).

479 **Table 1.** qPCR primer and probe sequences

Name	Sequence (5' to 3')*	Reference
N1-Forward	GACCCCAAAATCAGCGAAAT	USCDC[11]
N1-Reverse	TCTGGTTACTGCCAGTTGAATCTG	USCDC[11]
N1-Probe	6FAM-ACCCCGCATTACGTTTGGTGGACC-MGBNFQ	USCDC[11]

480 *6FAM, 6-carboxyfluorescein; MGBNFQ, Minor Groove Binder non-fluorescent quencher

481

482 **Table 2.** Built environment swab SARS-CoV-2 detection by location and characteristics.

	Campus A		Campus B		Total	
	Detected (N=39)	Not-Detected (N=451)	Detected (N=22)	Not-Detected (N=451)	Detected (N=61)	Not-Detected (N=902)
Unit COVID Risk Type						
COVID Risk Unit	17 (43.6%)	150 (33.3%)	17 (77.3%)	126 (27.9%)	34 (55.7%)	276 (30.6%)
Non-COVID Unit	9 (23.1%)	221 (49.0%)	5 (22.7%)	266 (59.0%)	14 (23.0%)	487 (54.0%)
Public/HCW Area	13 (33.3%)	80 (17.7%)	0 (0%)	59 (13.1%)	13 (21.3%)	139 (15.4%)
Object/Site						
Air (Control)	0 (0%)	10 (2.2%)	0 (0%)	10 (2.2%)	0 (0%)	20 (2.2%)
Computer Keyboard	0 (0%)	75 (16.6%)	1 (4.5%)	77 (17.1%)	1 (1.6%)	152 (16.9%)
Door Handle	0 (0%)	88 (19.5%)	0 (0%)	97 (21.5%)	0 (0%)	185 (20.5%)
Elevator Buttons	4 (10.3%)	46 (10.2%)	2 (9.1%)	57 (12.6%)	6 (9.8%)	103 (11.4%)
Exterior Bench	1 (2.6%)	9 (2.0%)	0 (0%)	0 (0%)	1 (1.6%)	9 (1.0%)
Floor	32 (82.1%)	59 (13.1%)	19 (86.4%)	78 (17.3%)	51 (83.6%)	137 (15.2%)
Hand Sanitizer	1 (2.6%)	49 (10.9%)	0 (0%)	59 (13.1%)	1 (1.6%)	108 (12.0%)
Other Item	1 (2.6%)	37 (8.2%)	0 (0%)	10 (2.2%)	1 (1.6%)	47 (5.2%)
Table	0 (0%)	3 (0.7%)	0 (0%)	2 (0.4%)	0 (0%)	5 (0.6%)
Telephone Receiver	0 (0%)	75 (16.6%)	0 (0%)	61 (13.5%)	0 (0%)	136 (15.1%)
Material						
Air (Control)	0 (0%)	10 (2.2%)	0 (0%)	9 (2.0%)	0 (0%)	19 (2.1%)
Metal	2 (5.1%)	120 (26.6%)	2 (9.1%)	154 (34.1%)	4 (6.6%)	274 (30.4%)
Plastic/Vinyl	37 (94.9%)	318 (70.5%)	20 (90.9%)	287 (63.6%)	57 (93.4%)	605 (67.1%)
Wood	0 (0%)	3 (0.7%)	0 (0%)	1 (0.2%)	0 (0%)	4 (0.4%)
Week						
1	7 (17.9%)	41 (9.1%)	4 (18.2%)	44 (9.8%)	11 (18.0%)	85 (9.4%)
2	6 (15.4%)	43 (9.5%)	2 (9.1%)	45 (10.0%)	8 (13.1%)	88 (9.8%)
3	6 (15.4%)	40 (8.9%)	3 (13.6%)	45 (10.0%)	9 (14.8%)	85 (9.4%)
4	8 (20.5%)	39 (8.6%)	2 (9.1%)	46 (10.2%)	10 (16.4%)	85 (9.4%)
5	3 (7.7%)	47 (10.4%)	3 (13.6%)	43 (9.5%)	6 (9.8%)	90 (10.0%)
6	3 (7.7%)	47 (10.4%)	2 (9.1%)	44 (9.8%)	5 (8.2%)	91 (10.1%)
7	3 (7.7%)	47 (10.4%)	3 (13.6%)	45 (10.0%)	6 (9.8%)	92 (10.2%)
8	2 (5.1%)	48 (10.6%)	1 (4.5%)	46 (10.2%)	3 (4.9%)	94 (10.4%)
9	1 (2.6%)	49 (10.9%)	0 (0%)	47 (10.4%)	1 (1.6%)	96 (10.6%)
10	0 (0%)	50 (11.1%)	2 (9.1%)	46 (10.2%)	2 (3.3%)	96 (10.6%)

483

484

485 **Table 3.** Swab characteristics and measure of association with SARS-CoV-2 detection.

Characteristic	Beta	95% CI[1]	p-value
Study Week	-0.01	-0.02, -0.01	<0.001
Material			
Metal	—	—	
Air (Control)	0.12	-0.32, 0.56	0.6
Plastic/Vinyl	0.07	0.00, 0.14	0.065
Wood	-0.02	-0.50, 0.46	>0.9
Specific Site			
Air (Control)	—	—	
Computer Keyboard	0.05	-0.38, 0.47	0.8
Door Handle	0.10	-0.33, 0.53	0.6
Elevator Buttons	0.18	-0.25, 0.61	0.4
Exterior Bench	0.20	-0.25, 0.66	0.4
Floor	0.31	-0.11, 0.74	0.15
Hand Sanitizer	0.05	-0.37, 0.48	0.8
Other Item	0.05	-0.38, 0.47	0.8
Table	0.05	-0.55, 0.65	0.9
Telephone Receiver	0.04	-0.39, 0.47	0.9
Unit COVID Risk Type			
Non-COVID Unit	—	—	
COVID Risk Unit	0.08	0.05, 0.11	<0.001
Public/HCW Area	0.02	-0.02, 0.06	0.3
Campus			
Campus B	—	—	
Campus A	0.03	0.00, 0.06	0.033

[1] CI = Confidence Interval

486

487

488 **Table 4.** Univariate coefficients with 95% confidence intervals (CI), p-values, and Akaike
489 information criterion (AIC) for prediction of hospital case burden from (i) proportion of built
490 environment swabs positive and (ii) proportion of floor swabs positive.
491

Variable	Coefficient	95% CI	P-value	AIC
All Built Environment Swabs	5.8	1-11	0.02	56.5
Floor Swabs	1.7	0.5-3.1	0.01	54.9

492
493



Figure 1. Limit of Detection analysis of SARS-CoV-2 RNA and virus standards. Serial dilutions of (A) SARS-CoV-2 RNA standard and (B) nucleic acid extractions of heat-inactivated virus were analyzed by qPCR targeting the N1 gene. Mean Cq values and standard deviations are plotted for 14-20 replicates (RNA standard) or 7 replicates (viral extractions). Grey circles indicate replicates that were not detected (ND). The limit of detection (red line with shaded 95% confidence interval) and limit of quantification (blue line) for the RNA standard were estimated by a model-fitting approach. The LOD for the viral extractions was estimated by a discrete threshold of >95% positivity. Equations, R^2 values, and amplification efficiency (E) are shown for each standard curve.



506

507 **Figure 2.** Swabbing recovery of heat-inactivated SARS-CoV-2 virus from spiked surfaces. Test
508 surfaces were spotted with 10^5 copies of the virus standard, allowed to dry, and swabbed for 30
509 seconds. Swabs were stored in nucleic acid stabilization solution overnight, RNA was extracted,
510 and recovered genome copies were quantified by qPCR analysis. Virus recovery was
511 determined by dividing the copies estimated for each sample by the copies estimated for a "no
512 swabbing" control. The mean and standard error for three replicates is shown. Letters indicate
513 significant differences between groups, determined by one-way ANOVA followed by Tukey's
514 post hoc test.

515



Figure 3. Time series of built environment swabs positive for SARS-CoV-2 by COVID risk location. **Blank (white) cells represent weeks where no swab was collected for a given location.*

521 (A)



522

523 (B)



524

525 **Figure 4.** Proportion of hospital built environment swabs positive for SARS-CoV-2 (bars) and [A]

526 mean hospital COVID-19 active cases (line) or [B] mean citywide COVID-19 active cases (line).

527

528 (A)



529

530 (B)



531

532 **Figure 5.** A. Proportion of hospital floor swabs positive for SARS-CoV-2 (bars) and [A] mean

533 hospital COVID-19 active cases (line) or [B] mean citywide COVID-19 active cases (line).

534

535

(A)



(B)



Figure 6. Campus A wastewater SAR-CoV-2 copies per ml (bars) and [A] mean citywide COVID-19 active cases (line) or [B] mean hospital COVID-19 active cases (line). There was no sample collection on weeks 7, 8 and 10.